

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Pr **CERVIDIL**®

Dinoprostone Vaginal Insert
Insert, 10 mg, For Vaginal Use
Prostaglandin

Ferring Inc.
200 Yorkland Blvd., Suite500
Toronto, Ontario
M2J 5C1

Date of Initial Authorization:
Apr 01, 1997

Date of Revision:
Aug 15, 2022

Submission Control Number: 263036

RECENT MAJOR LABEL CHANGES

2 CONTRAINDICATIONS	08/2022
4 DOSAGE AND ADMINISTRATION	08/2022
7 WARNINGS AND PRECAUTIONS, General	08/2022

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	5
4.3 Reconstitution.....	5
4.4 Administration	5
4.5 Missed Dose	8
5 OVERDOSAGE	8
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	8
7 WARNINGS AND PRECAUTIONS	9
7.1 Special Populations	11
7.1.1 Pregnant Women	11
7.1.2 Breast-feeding.....	11
7.1.3 Pediatrics.....	11
7.1.4 Geriatrics.....	11
8 ADVERSE REACTIONS	11
8.2 Clinical Trial Adverse Reactions	11

8.3	Less Common Clinical Trial Adverse Reactions.....	13
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	13
8.5	Post-Market Adverse Reactions.....	13
9	DRUG INTERACTIONS	14
9.4	Drug-Drug Interactions	14
9.5	Drug-Food Interactions.....	14
9.6	Drug-Herb Interactions	14
9.7	Drug-Laboratory Test Interactions.....	14
10	CLINICAL PHARMACOLOGY.....	14
10.1	Mechanism of Action	14
10.2	Pharmacodynamics.....	15
10.3	Pharmacokinetics.....	15
11	STORAGE, STABILITY AND DISPOSAL.....	16
12	Special Handling Instructions.....	16
PART II: SCIENTIFIC INFORMATION		17
13	PHARMACEUTICAL INFORMATION	17
14	CLINICAL TRIALS	17
14.1	Trial Design and Study Demographics	17
14.2	Study Results.....	17
16	NON-CLINICAL TOXICOLOGY	18
PATIENT MEDICATION INFORMATION		19

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

CERVIDIL® (dinoprostone vaginal insert) is indicated for:

- Initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labour.

1.1 Pediatrics

Pediatrics (<18 years of age):

CERVIDIL has not been studied in this patient population and is not recommended for use.

1.2 Geriatrics

Geriatrics (> 65 years of age):

CERVIDIL has not been studied in this patient population and is not recommended for use.

2 CONTRAINDICATIONS

CERVIDIL is contraindicated in:

- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- Patients when labour has started.
- Patients in whom there is clinical suspicion or definite evidence of fetal distress where delivery is not imminent.
- Patients with placenta previa or unexplained vaginal bleeding during this pregnancy.
- Patients in whom there is evidence or strong suspicion of marked cephalopelvic disproportion.
- Patients in whom uterotonic drugs are contraindicated or when prolonged contraction of the uterus may be detrimental to fetal safety or uterine integrity (previous caesarean section or major uterine surgery) (see [7 WARNINGS AND PRECAUTIONS](#), and [8 ADVERSE REACTIONS](#)).
- Patients who have had previous major uterine cervix surgery (e.g. other than biopsies and cervical abrasion) or rupture of the uterine cervix.
- Multipara with 6 or more previous term pregnancies.
- Patients with a history of difficult labour and/or traumatic delivery.
- Patients with overdistension of uterus (multiple pregnancy, polyhydramnios).
- Patients with fetal malpresentation.
- Patients with a history of epilepsy whose seizures are poorly controlled.
- CERVIDIL should not be used simultaneously with other uterotonic drugs and/or other

labour induction agents (See [7 WARNINGS AND PRECAUTIONS](#)).

- CERVIDIL should not be used when there is a history of, or current pelvic inflammatory disease, unless adequate prior treatment has been instituted.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

For Hospital Use Only:

CERVIDIL should be administered only by trained obstetrical personnel in a hospital setting with appropriate obstetrical care facilities.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- In case of subsequent administration of uterotonic drugs, a dosing interval of at least 30 minutes is recommended following the removal of the vaginal delivery system.

4.2 Recommended Dose and Dosage Adjustment

- CERVIDIL is used as a single dosage in a single application. The dosage of dinoprostone in the vaginal insert is 10 mg designed to be released at approximately 0.3 mg/hour over a 12 hour period. CERVIDIL should be removed upon onset of active labour, 12 hours after insertion, or in the event of an adverse reaction, e.g., uterine hyperstimulation.

4.3 Reconstitution

CERVIDIL requires no reconstitution prior to use.

4.4 Administration

CERVIDIL should be removed from the freezer just prior to the insertion. No thawing is required prior to use.

To remove CERVIDIL from the packaging, first tear the foil along the top of the sachet. Do not use scissors or sharp implements to cut the foil as this may damage the product. Use the retrieval system to gently pull the product out of the sachet.

CERVIDIL is a thin, flat, semi-transparent polymeric slab which is rectangular in shape with rounded corners contained within a knitted polyester retrieval system.

Insertion

One CERVIDIL is placed transversely high in the posterior fornix of the vagina immediately after removal from its foil package. The insertion of the vaginal insert does not require sterile conditions. The vaginal insert must not be used without its retrieval system. There is no need for previous warming of the product. A minimal amount of water-miscible lubricant may be used to assist in insertion of CERVIDIL. Care should be taken not to permit excess contact or coating with the lubricant and thus prevent optimal swelling and release of dinoprostone from the vaginal insert. Patients should remain in the supine position for 2 hours following insertion, but thereafter may be ambulatory. It is important to monitor uterine contractions and fetal condition at frequent regular intervals.

How to properly insert CERVIDIL



Start

Pick up the insert between 2 fingers, positioning the slab end to be inserted first, and extend the tape



Prepare

Apply a minimal amount of water-miscible lubricant to 2 fingers (not to the slab itself)



Insert

Gently place your 2 fingers with the insert into the vagina



Properly Position Insert

Position the insert transversely (like a boomerang) high in the posterior vaginal fornix



Secure

After inserting, the retrieval tape may be cut with scissors, leaving a small portion of the tail outside of the vagina to allow for removal



Don't

Do not wrap the tape around the insert or cut the tape from the slab

Removal

The retrieval system consists of a one-piece knitted polyester pouch and retrieval tape. This ensures easy and reliable removal of the insert when the patient's requirement for PGE₂ has been fulfilled or an obstetric event makes it necessary to stop further drug administration.

CERVIDIL can be removed quickly and easily by pulling gently on the retrieval tape. On removal of the product from the vagina, the vaginal delivery system will have swollen to 2-3 times its original size and be pliable.

After removal from the patient, ensure that the entire product (vaginal delivery system and retrieval system) has been removed from the vagina.

It is necessary to remove the vaginal delivery system to terminate drug administration when cervical ripening is judged to be complete or for any of the reasons listed below.

1. Onset of labour. For the purposes of induction of labour with CERVIDIL, the onset of labour is defined as the presence of regular painful uterine contractions occurring every 3 minutes irrespective of any cervical change. There are two important points to note:
 - (i) Once regular, painful contractions have been established with CERVIDIL, they will not reduce in frequency or intensity as long as CERVIDIL remains in situ because dinoprostone is still being administered.
 - (ii) Patients, particularly multigravidae, may develop regular painful contractions without any apparent cervical change. Effacement and dilatation of the cervix may

not occur until uterine activity is established. Because of this, once regular painful uterine activity is established with CERVIDIL in-situ, the vaginal delivery system should be removed irrespective of cervical state to avoid the risk of uterine hyperstimulation.

2. Spontaneous rupture of the membranes or amniotomy.
3. Any suggestion of uterine hyperstimulation or hypertonic uterine contractions.
4. Evidence of fetal distress.
5. Evidence of maternal systemic adverse dinoprostone effects such as nausea, vomiting, hypotension or tachycardia.
6. At least 30 minutes prior to starting an intravenous infusion of uterotonic drugs.

4.5 Missed Dose

Not applicable. CERVIDIL is only used once.

5 OVERDOSAGE

Overdosage is usually manifested by uterine hyperstimulation which may be accompanied by fetal distress and is responsive to removal of the insert. Other treatment must be symptomatic, since to date, clinical experience with prostaglandin antagonists is insufficient.

The use of beta-adrenergic agents should be considered in the event of undesirable increased uterine activity.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Vaginal	Insert / 10 mg dinoprostone	Insert: Cross-linked polyethylene oxide / urethane polymer slab Retrieval system: Polyester yarn

CERVIDIL is available in a carton containing 1 insert within a retrieval system, enclosed in foil (aluminium/polyethylene) pack.

Each insert contains 10 mg of dinoprostone. The insert and its retrieval system are non-toxic and when placed in a moist environment, absorbs water, swells, and releases dinoprostone.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

General

The condition of the cervix should be assessed carefully before CERVIDIL is used. After insertion, uterine activity and fetal condition must be monitored carefully and regularly by a qualified healthcare professional. If there is any suggestion of maternal or fetal complications or if adverse effects occur, the vaginal delivery system should be removed from the vagina.

Since prostaglandins potentiate the effect of uterotonic drugs, CERVIDIL must be removed before uterotonics administration is initiated and the patient's uterine activity carefully monitored for uterine hyperstimulation.

If uterine hyperstimulation is encountered or if labour commences, the vaginal insert should be removed. CERVIDIL should also be removed prior to amniotomy. The vaginal insert should be removed if there is evidence of maternal systemic adverse PGE₂ effects such as nausea, vomiting, hypotension or tachycardia.

The experience of CERVIDIL in patients with ruptured membranes is limited. Therefore, CERVIDIL should be used with caution in those patients. Since the release of dinoprostone from the insert can be affected in the presence of amniotic fluid, special attention should be given to uterine activity and fetal condition.

Caution should be exercised in the administration of CERVIDIL for cervical ripening in patients with a history of previous uterine hypertonicity, glaucoma, or a history of childhood asthma, even though there have been no asthma attacks in adulthood or unexplained genital bleeding during the current pregnancy.

CERVIDIL should be used with caution when there is a multiple pregnancy. No studies in multiple pregnancy have been performed.

CERVIDIL should be used with caution when the woman has had more than three full term deliveries. No studies in woman with more than three full term deliveries have been performed.

A second dose of CERVIDIL is not recommended, as the effects of a second dose have not been studied.

The use of the product in patients with diseases which could affect the metabolism or excretion of dinoprostone, e.g. lung, liver or renal disease, has not been specifically studied. The use of the product in such patients is not recommended.

Women aged 35 and over, women with complications during pregnancy, such as gestational diabetes, arterial hypertension and hypothyroidism, and women at gestational age above 40 weeks, have a higher postpartum risk for developing disseminated intravascular coagulation (DIC). These factors may additionally enhance the risk of disseminated intravascular coagulation in women with pharmacologically induced labour (see [8 ADVERSE REACTIONS](#)). Therefore, dinoprostone should be used with caution in these women. In the immediate postpartum phase, the physician should look carefully for early signs of developing DIC (e.g. fibrinolysis).

Uterine activity, fetal status and the progression of cervical dilatation and effacement should be carefully monitored whenever the dinoprostone vaginal insert is in place. Any evidence of uterine hyperstimulation, sustained uterine contractions, fetal distress, or other fetal or maternal adverse reactions, should be a cause for consideration of removal of the insert. The possibility of uterine rupture and/or cervical laceration should be born in mind where hypertonic myometrial contractions are sustained.

Uterine rupture has been reported in association with the use of CERVIDIL, mainly in patients with contraindicated conditions (see [2 CONTRAINDICATIONS](#)). Therefore, CERVIDIL should not be administered to patients with a history of previous caesarean section or uterine surgery given the potential risk for uterine rupture and associated obstetrical complications. If uterine contractions are prolonged or excessive, there is possibility of uterine hypertonus or rupture and the vaginal delivery system should be removed immediately.

Cephalopelvic relationships should be carefully evaluated before the use of CERVIDIL. Prolonged treatment of newborn infants with prostaglandin E₁ can induce proliferation of bone. There is no evidence that short term administration of prostaglandin E₂ can cause similar bone effects.

Patients with severe renal disease and/or severe hepatic disease accompanied by metabolic aberrations should be dosed with caution.

The qualified healthcare professional should be alert that, as with other labour induction methods, use of dinoprostone may result in inadvertent abruption of placenta and subsequent embolization of antigenic tissue causing in rare circumstances the development of Anaphylactoid Syndrome of Pregnancy (Amniotic Fluid Embolism).

Carcinogenesis and Mutagenesis

Long-term carcinogenicity and fertility studies have not been conducted with CERVIDIL (dinoprostone vaginal insert). No evidence of mutagenicity has been observed with prostaglandin E₂ in the Unscheduled DNA Synthesis Assay, the Micronucleus Test, or Ames Assay.

Monitoring and Laboratory Tests

After insertion, the patient should remain supine and monitored for 2 hours for any evidence

of uterine hyperstimulation, change in fetal heart rate or maternal blood pressure or heart rate.

If any of these changes occur, removal of CERVIDIL should be considered.

7.1 Special Populations

7.1.1 Pregnant Women

Animal studies indicate that the prostaglandins may be teratogenic. No effect would be expected clinically, when used as indicated, since CERVIDIL (dinoprostone vaginal insert) is administered after the period of organogenesis. Any dose of the drug that produces sustained increased uterine tone could put the embryo or fetus at risk.

7.1.2 Breast-feeding

CERVIDIL is not indicated for use during early or other phases of pregnancy or during lactation.

7.1.3 Pediatrics

Pediatrics (< 18 years): CERVIDIL has not been studied in this patient population and is not recommended for use.

7.1.4 Geriatrics

Geriatrics (> 65 years): CERVIDIL has not been studied in this patient population and is not recommended for use.

8 ADVERSE REACTIONS

8.2 Clinical Trial Adverse Reactions

Controlled Studies and Study 101-801

Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

CERVIDIL is well tolerated. In placebo-controlled trials in which 658 women were entered and 320 received active therapy (218 without retrieval system, 102 with retrieval system), the following events were reported. See [Table 1](#).

Miso-Obs Studies

The most commonly reported adverse drug reactions in placebo-controlled and active comparator efficacy clinical trials (N=1116) were “fetal heart rate disorder” (6.9 %), “uterine contractions abnormal” (6.2 %) and “abnormal labour affecting fetus” (2.6 %).

Table 1 – Total Drug Related Adverse Events (Controlled Studies and Study 101-801)

	Controlled Studies ¹		Study 101-801 ²	
	Active	Placebo	Active	Placebo
Uterine hyperstimulation with fetal distress	2.8%	0.3%	2.9%	0%
Uterine hyperstimulation without fetal distress	4.7%	0%	2.0%	0%
Fetal Distress without uterine hyperstimulation	3.8%	1.2%	2.9%	1.0%
N	320	338	102	104
¹ Controlled Studies (with and without retrieval system)				
² Controlled Study (with retrieval system)				

Drug related fever, nausea, vomiting, diarrhea, and abdominal pain were noted in less than 1% of patients who received CERVIDIL.

The table below displays the main ADRs distributed by system organ classes (SOC) and frequency:

Table 2 – Frequency of reported adverse reactions (Miso-Obs Studies)

System organ class	Common (≥ 1/100 to < 1/10)	Uncommon (≥ 1/1000 to < 1/100)
Immune system disorders		
Nervous system disorders		Headache
Cardiac disorders	Fetal heart rate disorder ^{1*}	
Vascular disorders		Hypotension
Respiratory, thoracic and mediastinal disorders		Neonatal respiratory distress related conditions
Hepatobiliary disorders		Neonatal hyperbilirubinemia
Skin and subcutaneous tissue disorders		Pruritus
Pregnancy, puerperium and perinatal conditions	Abnormal labour affecting fetus ^{2*} Uterine contractions abnormal, uterine tachysystole, uterine hyperstimulation, uterine hypertonus ^{3*} Meconium in amniotic fluid	Postpartum haemorrhage, Premature separation of placenta, Apgar score low Arrested labour Chorioamnionitis Uterine atony
Reproductive system and breast disorders		Vulvovaginal burning sensation
General disorders and administration site conditions		Febrile disorders
1* "Fetal heart rate disorder" was in clinical studies reported as "fetal heart rate		

System organ class	Common (≥ 1/100 to < 1/10)	Uncommon (≥ 1/1000 to < 1/100)
<p>abnormalities”, “fetal bradycardia”, “fetal tachycardia”, “unexplained absence of normal variability”, “fetal heart rate decreased”, “fetal heart rate deceleration”, “early or late decelerations”, “variable decelerations”, “prolonged decelerations”.</p> <p>2* “Abnormal labour affecting fetus” as expression for hyperstimulation syndrome was in clinical studies reported as “uterine tachysystole” combined with “late decelerations”, “fetal bradycardia”, or “prolonged decelerations”.</p> <p>3* Fetal death, stillbirth, and neonatal death have been reported after application of dinoprostone, especially following the occurrence of serious events such as uterine rupture (see 2 CONTRAINDICATIONS, 4 DOSAGE AND ADMINISTRATION, and 7 WARNINGS AND PRECAUTIONS).</p>		

8.3 Less Common Clinical Trial Adverse Reactions

An increased risk of post-partum disseminated intravascular coagulation has been reported in patients whose labour was induced by pharmacological means, either with dinoprostone or oxytocin. The frequency of this adverse event, however, appears to be rare (<1 per 1,000 pregnancies).

Very rare cases of anaphylactic reactions have been reported with the use of dinoprostone.

In Study 101-801 (with the retrieval system) all cases of hyperstimulation reversed within 2 to 13 minutes of removal of the product. Tocolytics were required in one of the five cases. In cases of fetal distress, when product removal was thought advisable, there was a return to normal rhythm and no neonatal sequelae.

Five minute Apgar scores were 7 or above in 98.2% (646/658) of studied neonates whose mothers participated in placebo-controlled studies with CERVIDIL. A 3 year pediatric follow-up study in 121 infants whose mothers received PGE₂, found no significant differences from a control group on physical examination or psychomotor evaluation.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

No information is available.

8.5 Post-Market Adverse Reactions

The ADRs seen during post-marketing experience are listed below with unknown frequency by system organ class followed by adverse reactions.

Immune system disorders: Hypersensitivity

Gastrointestinal disorders: Abdominal pain, Nausea, vomiting, diarrhea

Pregnancy, puerperium and perinatal conditions: Anaphylactoid syndrome of pregnancy, Fetal distress syndrome *

Reproductive system and breast disorders: Genital edema

Injury, poisoning and procedural complications: Uterine rupture

* "Fetal distress syndrome" was also reported as "fetal acidosis", "pathological CTG", "fetal heart rate abnormalities", "intrauterine hypoxia" or "threatening asphyxia". The term itself is unspecific, has a low positive predictive value and is often associated with an infant who is in good condition at birth.

9 DRUG INTERACTIONS

9.4 Drug-Drug Interactions

CERVIDIL may augment the activity of oxytocic agents and their concomitant use is not recommended. A dosing interval of at least 30 minutes is recommended for the sequential use of oxytocin following the removal of the dinoprostone vaginal insert. No other drug interactions have been identified.

Medication with non-steroidal anti-inflammatory drugs, including acetylsalicylic acid, should be stopped before administration of dinoprostone.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Dinoprostone (PGE₂) is a naturally-occurring biomolecule. It is found in low concentrations in most tissues of the body and functions as a local hormone. As with any local hormone, it is very rapidly metabolized in the tissues of synthesis. The rate limiting step for inactivation is regulated by the enzyme 15-hydroxyprostaglandin dehydrogenase (PGDH). Any PGE₂ that

escapes local inactivation is rapidly cleared to the extent of 95% on the first pass through the pulmonary circulation.

In pregnancy, PGE₂ is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labour. It is known that PGE₂ stimulates the production of PGF_{2α} which in turn sensitizes the myometrium to endogenous or exogenously administered oxytocin. Although PGE₂ is capable of initiating uterine contractions and may interact with oxytocin to increase uterine contractility, the available evidence indicates, that in the concentrations found during the early part of labour, PGE₂ plays an important role in cervical ripening without affecting uterine contractions. This distinction serves as the basis for considering cervical ripening and induction of labour, usually by the use of oxytocin, as two separate processes.

PGE₂ plays an important role in the complex set of biochemical and structural alterations involved in cervical ripening. Cervical ripening involves a marked relaxation of the cervical smooth muscle fibers of the uterine cervix which must be transformed from a rigid structure to a softened, yielding and dilated configuration to allow passage of the fetus through the birth canal. This process involves activation of the enzyme collagenase, which is responsible for digestion of some of the structural collagen network of the cervix. This is associated with a concomitant increase in the amount of hydrophilic glycosaminoglycan, hyaluronic acid, and a decrease in dermatan sulfate. Failure of the cervix to undergo these natural physiologic changes, usually assessed by the method described by Bishop, prior to the onset of effective uterine contractions, results in an unfavourable outcome for successful vaginal delivery and may result in fetal compromise. It is estimated that in approximately 5% of the pregnancies the cervix does not ripen normally. In an additional 10-11% of pregnancies, labour must be induced for medical or obstetric reasons prior to the time of cervical ripening.

10.2 Pharmacodynamics

Prostaglandin E₂ (PGE₂) is a naturally occurring compound found in low concentrations in most tissues of the body. It functions as a local hormone.

Prostaglandin E₂ plays an important role in the complex set of biochemical and structural alterations involved in cervical ripening. Cervical ripening involves a marked relaxation of the cervical smooth muscle fibres of the uterine cervix which must be transformed from a rigid structure to a soft, dilated configuration to allow passage of the fetus through the birth canal. This process involves activation of the enzyme collagenase which is responsible for the breakdown of the collagen.

Local administration of dinoprostone to the cervix results in cervical ripening which then induces the subsequent events which complete labour.

10.3 Pharmacokinetics

PGE₂ is rapidly metabolised primarily in the tissue of synthesis.

No correlation could be established between PGE₂ release and plasma concentrations of its metabolite, PGE_m. The relative contributions of endogenously and exogenously released PGE₂ to the plasma levels of the metabolite PGE_m could not be determined.

The reservoir of 10 mg dinoprostone serves to maintain a controlled and constant release. The release rate is approximately 0.3 mg per hour over 12 hours in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes. CERVIDIL releases dinoprostone to the cervical tissue continuously at a rate which allows cervical ripening to progress until complete, and with the facility to remove the dinoprostone source when the clinician decides that cervical ripening is complete or labour has started, at which point no further dinoprostone is required.

11 STORAGE, STABILITY AND DISPOSAL

Store in a freezer between -20°C and -10°C.

Store in the original container in order to protect from moisture. No thawing is required prior to use.

12 SPECIAL HANDLING INSTRUCTIONS

CERVIDIL should be removed from the freezer just prior to the insertion.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: Dinoprostone

- (1) Chemical name: Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-,(5Z,11 α ,13E,-15S)-
- (2) (E,Z)-(1R,2R,3R)-7-[3-Hydroxy-2-[(3S)-(3-hydroxy-1-octenyl)]-5-oxocyclopentyl]-5-heptenoic acid
- (3) Prostaglandin E₂

Molecular formula and molecular mass: C₂₀H₃₂O₅ and 352.47

Structural formula:



Physicochemical properties:

Dinoprostone occurs as a white to off-white crystalline powder. It has a melting point within the range of 65° to 68°C. Dinoprostone is freely soluble in ethanol, methylene chloride, ethyl acetate and chloroform, and very slightly soluble in n-hexane. Aqueous solubility is 1.05 mg/mL at 25°C.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The clinical subjects were primiparous and multiparous.

14.2 Study Results

Treatment success in three double-blind, placebo-controlled studies was defined as Bishop score increase at 12 hours of ≥ 3 , vaginal delivery within 12 hours or Bishop score at 12 hours ≥ 6 . Results in a total of 603 (283 active, 320 placebo) qualified patients demonstrated success rates of 69.4% and 71.7% for primiparous and multiparous, respectively compared to placebo values of 29.7% for both groups.

Of the 658 patients evaluable for safety in the double-blind trials (320 active, 338 placebo), 9

patients (2.8%) who received the active insert experienced tachysystole associated with fetal distress, while 15 patients (4.7%) experienced hyperstimulation without fetal distress. Removal of the insert resulted in relief of the symptomatology and in no case was there evidence of a neonatal adverse event.

16 NON-CLINICAL TOXICOLOGY

Toxicology studies have been conducted on PGE₂, on the hydrogel polymer and on the insert retrieval system.

There is little information specifically related to PGE₂ toxicity because of its rapid inactivation in the body. A study in chicken embryos and newly hatched chicks showed that there was no discernable PGE₂-related lethality following administration of doses between 10⁻⁵ and 10⁻⁸ M to embryos and proportionally larger doses to chicks.

The hydrogel polymer showed no evidence of toxicity in a cytotoxicity study in mouse fibroblast cultures or in an intramuscular implantation test in rabbits. Dietary and oral toxicity studies of the hydrogel polymer in rats and dogs were conducted for periods between 10 and 36 days and showed no evidence of toxicity.

In vitro unscheduled DNA synthesis assays on primary rat hepatocytes showed no evidence of mutagenicity for PGE₂ at doses up to 5,000 mcg/mL.

PGE₂ administered subcutaneously to female mice at doses up to 50 mcg/kg/day during days 11 to 17 of pregnancy had a masculinizing effect on the genital tract of female fetuses. The results of this study and a related *in vitro* study using female genital duct cultures suggest that PGE₂ plays a role in androgen-dependent masculine differentiation.

The insert retrieval system which is composed of the polyester material Dacron T56 and the material itself were evaluated in *in vitro* cytotoxicity tests, systemic toxicity tests in mice, intramuscular implantation tests in rabbits, hemolysis tests, pyrogenicity tests, intracutaneous reactivity tests in rabbits, skin irritation tests in guinea pigs and vaginal irritation tests in rabbits. There was no evidence of toxicity in any of the studies.

The results of an *in vitro* test using *Staphylococcus aureus* predict no association between the use of the hydrogel insert and toxic shock syndrome.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PrCERVIDIL

Dinoprostone Vaginal Insert

Read this carefully before you start taking **CERVIDIL** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **CERVIDIL**.

Serious Warnings and Precautions

For Hospital Use Only: CERVIDIL is only available and for use in hospitals with the appropriate care facilities. Your healthcare professional will determine if CERVIDIL is right for you. If CERVIDIL is deemed necessary, it will be administered by trained obstetrical healthcare professionals.

What is CERVIDIL used for?

CERVIDIL is used in adult women during the birthing process at the end of pregnancy. It helps to start or continue cervical ripening (softening and opening of the cervix) before labour.

How does CERVIDIL work?

CERVIDIL vaginal insert contains dinoprostone, which is similar to a natural substance in the body called prostaglandin. During the birthing process the cervix (part of the birth canal) needs to relax and dilate (open) prior to labour. Dinoprostone signals to the body to help the cervix gradually soften, thin, and dilate to allow the baby through.

What are the ingredients in CERVIDIL?

Medicinal ingredient: Dinoprostone

Non-medicinal ingredients:

- **Insert:** Cross-linked polyethylene oxide / urethane polymer slab.
- **Retrieval system:** Polyester yarn.

CERVIDIL comes in the following dosage forms:

Vaginal insert, 10 mg of dinoprostone

Do not use CERVIDIL if:

- you are allergic to dinoprostone or any of the other ingredients of CERVIDIL.
- you are in labour or if labour has just started.
- your baby is suspected to be distressed and/or not in good health.
- the placenta is partially or completely covering the opening of the cervix (placenta previa).
- you have or have had any unexplained vaginal bleeding during this pregnancy.
- the size of your baby's head may cause any problems during pregnancy.
- you have contractions that are too strong or prolonged.
- you have had previous surgery or rupture of the cervix (e.g., a previous caesarean section).
- you have had 6 or more pregnancies.
- you had previous difficulties during labour or a traumatic delivery.
- your baby is not in the correct position in the womb to be born naturally.
- you have a history of seizures.
- you are taking other uterotonic or labour induction agents (medicines used to help start labour).
- you cannot take uterotonic medicines for any reason.
- you have untreated pelvic inflammatory disease (an infection in the womb, ovaries, tubes, and/or cervix).
- your uterus is larger than usual. This may happen if you have had a large baby, have too much amniotic fluid, or have had multiple pregnancies.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CERVIDIL. Talk about any health conditions or problems you may have, including if you:

- are in the early phases of pregnancy.
- are breastfeeding or planning to breastfeed.
- have kidney problems.
- have liver problems.
- have lung problems.
- are 35 years of age and over.
- have had complications during your pregnancy in the past (e.g., developing diabetes, high blood pressure, or low level of thyroid hormones).
- are at gestational age above 40 weeks.
- are planning an amniotomy, also known as artificial rupture of the membranes or AROM (artificially "breaking the water").
- have already broke your water (ruptured membranes).
- have glaucoma (increased pressure in your eye causing damage to the optic nerve).
- have a history of childhood asthma.

- have a history of hypertonic uterine contractions (contractions are too strong, too long, or more frequent).
- are planning to take uterotonic agents (medicines used to help start labour).
- have had more than three full-term deliveries.

Other warnings you should know about:

Monitoring and check-ups: Your healthcare professional will assess and monitor your health and the health of your baby before, during, and after your procedure with CERVIDIL. This may include assessing and monitoring:

- the size of your baby's head compared to your pelvis;
- your cervix (including dilation or thinning of your cervix);
- your contractions;
- your labour pains;
- your blood pressure;
- your heart rate; and
- the heart rate and distress of your baby.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with CERVIDIL:

- oxytocic agents, medicines used to induce labour.
- non-steroidal anti-inflammatory drugs (NSAIDs), medicines used to reduce pain and swelling such as acetylsalicylic acid or aspirin.

How CERVIDIL is used:

- Your healthcare professional will prepare and insert CERVIDIL for you. CERVIDIL may be coated with a small amount of lubricating jelly before it is inserted into your vagina. After CERVIDIL is inserted, there will be tape left outside of your vagina so it can be pulled out.
- You will be lying down during this procedure. You will have to stay that way for about 2 hours after CERVIDIL is inserted.
- When in place, CERVIDIL takes up some of the moisture there. This allows the medicinal ingredient, dinoprostone, to be slowly released.
- When the insert is removed, CERVIDIL may be swollen 2 to 3 times its original size and will be softer.

Usual dose:

The usual dose is one single CERVIDIL application. Your healthcare professional will decide how long CERVIDIL needs to be kept in place, depending on your progress. CERVIDIL can be left in place for a maximum of 12 hours.

Overdose:

You can overdose if CERVIDIL is inserted longer than 12 hours or longer than you need. An overdose can lead to increased contractions or distress for your baby. If this happens, your healthcare professional will remove the CERVIDIL insert by pulling on the retrieval string.

If you think you, or a person you are caring for, have received too much CERVIDIL, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

Not applicable. CERVIDIL is only used once.

What are possible side effects from using CERVIDIL?

These are not all the possible side effects you may feel when you are given CERVIDIL. If you experience any side effects not listed here, tell your healthcare professional.

The side effects of CERVIDIL may include:

- abdominal pain,
- burning sensation in the genital area,
- diarrhea,
- fever,
- headache,
- itchiness,
- nausea,
- vomiting.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Abnormal uterine problems: slow progression of labour, excessively frequent contractions, contractions that last longer than 2 minutes, heavy bleeding after giving birth, soreness in the genital area, shortness of breath, decreased urination, or blood clots.			✓
Amniotic fluid problems: discoloured amniotic fluid, infection of the amniotic fluid or placenta, fever, rapid heartrate, sweating, sore or painful uterus, or bad and unusual smelling discharge from the vagina.			✓
Fetal distress (fetus is not receiving enough oxygen): the baby has an abnormal heart rate, abrupt decreases in heart rate, decrease in movement, or discoloured amniotic fluid.			✓
Placental abruption (placenta separates from the wall of the womb): vaginal bleeding, abdominal pain, back pain, sore or rigid uterus, or frequent contractions.			✓
UNCOMMON			
Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, or fatigue (may occur when you go from lying or sitting to standing up).		✓	
VERY RARE			

Allergic reaction: difficulty swallowing or breathing, wheezing, drop in blood pressure, feeling sick to your stomach and throwing up, hives, rash, or swelling of the face, lips, tongue or throat.			✓
UNKNOWN FREQUENCY			
Anaphylactoid syndrome of pregnancy (ASP; anaphylactic reaction after amniotic fluid enters the mother’s blood): headaches, chest pain, cough, sweating, nausea, or vomiting.		✓	
Gastrointestinal problems: abdominal pain, nausea, vomiting, diarrhea, bloating		✓	
Genital edema (swelling of the genital area): pain or swelling in the genitals, painful or difficulty urinating, infections, thickening or hardening of the skin in the genital area, or trouble with sexual function.		✓	
Uterine rupture (tearing of the uterus): uterine pain, abnormal contractions, abdominal pain, high heart rate, low blood pressure, shock, fetal distress, or excessive vaginal bleeding.			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Your healthcare professional will store CERVIDIL in a freezer between -20°C and -10°C. Keep out of reach and sight of children.

If you want more information about CERVIDIL:

- Talk to your healthcare professional
- Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's, Ferring Inc.'s, website (www.ferring.ca), or by calling 1-866-384-1314.

This leaflet was prepared by Ferring Inc.

Last Revised Aug 15, 2022